Английская Википедия:Bimekizumab

Материал из Онлайн справочника
Версия от 13:15, 9 февраля 2024; EducationBot (обсуждение | вклад) (Новая страница: «{{Английская Википедия/Панель перехода}} {{Short description|Monoclonal antibody}} {{Use dmy dates|date=June 2023}} {{cs1 config |name-list-style=vanc |display-authors=6}} {{Infobox drug | type = mab | image = | alt = | caption = <!-- Monoclonal antibody data --> | mab_type = mab | source = zu | target = IL17A, Interleukin...»)
(разн.) ← Предыдущая версия | Текущая версия (разн.) | Следующая версия → (разн.)
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Use dmy dates Шаблон:Cs1 config Шаблон:Infobox drug

Bimekizumab, sold under the brand name Bimzelx, is a humanized anti-IL17A, anti-IL-17F, and anti-IL17AF monoclonal antibody[1][2] that is used to treat plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, and ankylosing spondylitis.[1]

The most common side effects include upper respiratory tract infections (nose and throat infection) and oral candidiasis (thrush, a fungal infection in the mouth or throat).[1] Injection site reactions were also common, reported in 3% of subjects.[3]

Bimekizumab was approved for medical use in the European Union in August 2021,[1][4][5] and in the United States in October 2023.[6][7]

Medical uses

In the EU, bimekizumab is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, non-radiographic axial spondyloarthritis, and active ankylosing spondylitis.[1]

History

Bimekizumab is being developed by Belgian pharmaceutical company UCB.Шаблон:Citation needed

Society and culture

Names

Bimekizumab is the international nonproprietary name (INN).[8]

Research

Phase III trials have demonstrated that bimekizumab is superior to not only adalimumab[9] but also secukinumab[10] and ustekinumab[11] for the treatment of plaque psoriasis.

References

Шаблон:Reflist

Further reading

Шаблон:Refbegin

Шаблон:Refend

Шаблон:Monoclonals for immune system Шаблон:Portal bar Шаблон:Authority control


Шаблон:Monoclonal-antibody-stub

Партнерские ресурсы
Криптовалюты
Магазины
Хостинг
Разное

  1. ↑ 1,0 1,1 1,2 1,3 1,4 Ошибка цитирования Неверный тег <ref>; для сносок Bimzelx EPAR не указан текст
  2. ↑ Шаблон:Cite journal
  3. ↑ Шаблон:Drugs.com
  4. ↑ Шаблон:Cite web
  5. ↑ Шаблон:Cite press release
  6. ↑ Шаблон:Cite web
  7. ↑ Шаблон:Cite press release
  8. ↑ Шаблон:Cite journal
  9. ↑ Шаблон:Cite journal
  10. ↑ Шаблон:Cite journal
  11. ↑ Шаблон:Cite journal
Источник — http://wikihandbk.com/ruwiki/index.php?title=Английская_Википедия:Bimekizumab&oldid=13527778